# Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

> **NCT01675882** · PHASE2 · COMPLETED · sponsor: **DBV Technologies** · enrollment: 221 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **BIOLOGICAL:** Viaskin Peanut 50 mcg
- **BIOLOGICAL:** Viaskin Peanut 100 mcg
- **BIOLOGICAL:** Viaskin Peanut 250 mcg
- **BIOLOGICAL:** Viaskin Placebo

## Key facts

- **NCT ID:** NCT01675882
- **Lead sponsor:** DBV Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01675882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01675882, "Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01675882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*